U.S. Markets close in 1 hr 23 mins
  • S&P 500

    3,806.77
    +21.39 (+0.57%)
     
  • Dow 30

    30,973.73
    +198.30 (+0.64%)
     
  • Nasdaq

    11,066.84
    +38.11 (+0.35%)
     
  • Russell 2000

    1,716.40
    +8.41 (+0.49%)
     
  • Crude Oil

    108.62
    +2.86 (+2.70%)
     
  • Gold

    1,808.00
    +0.70 (+0.04%)
     
  • Silver

    19.80
    -0.56 (-2.74%)
     
  • EUR/USD

    1.0429
    -0.0055 (-0.5214%)
     
  • 10-Yr Bond

    2.8880
    -0.0840 (-2.83%)
     
  • Vix

    26.90
    -1.81 (-6.30%)
     
  • GBP/USD

    1.2090
    -0.0085 (-0.7012%)
     
  • USD/JPY

    135.2690
    -0.4590 (-0.3382%)
     
  • BTC-USD

    19,504.13
    +468.15 (+2.46%)
     
  • CMC Crypto 200

    420.25
    +0.11 (+0.03%)
     
  • FTSE 100

    7,168.65
    -0.63 (-0.01%)
     
  • Nikkei 225

    25,935.62
    -457.42 (-1.73%)
     

BioCryst to Report Fourth Quarter 2021 Financial Results on February 23

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

RESEARCH TRIANGLE PARK, N.C., Feb. 09, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter and full year 2021 financial results Wednesday, February 23, 2022.

BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 877-303-8027 for domestic callers and 760-536-5165 for international callers and using conference ID # 6365545. A live webcast of the call and any slides will be available online at the investors section of the company website at www.biocryst.com. A telephone replay of the call will be available by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference ID # 6365545.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO® (berotralstat) is approved in the United States, the European Union, Japan, the United Kingdom and the United Arab Emirates. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB® (peramivir injection) has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the company’s website at www.biocryst.com.

BCRXW

Contact:
Investors
John Bluth
+1 919 859 7910
jbluth@biocryst.com

Media
Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com